

RESEARCH ARTICLE

Open Access



In vitro infectivity and differential gene expression of *Leishmania infantum* metacyclic promastigotes: negative selection with peanut agglutinin in culture versus isolation from the stomodeal valve of *Phlebotomus perniciosus*

Pedro J. Alcolea^{1*}, Ana Alonso¹, María A. Degayón¹, Mercedes Moreno-Paz², Maribel Jiménez³, Ricardo Molina³ and Vicente Larraga¹

Abstract

Background: *Leishmania infantum* is the protozoan parasite responsible for zoonotic visceral leishmaniasis in the Mediterranean basin. A recent outbreak in humans has been reported in this area. The life cycle of the parasite is digenetic. The promastigote stage develops within the gut of phlebotomine sand flies, whereas amastigotes survive and multiply within phagolysosomes of mammalian host phagocytes. The major vector of *L. infantum* in Spain is *Phlebotomus perniciosus*. The axenic culture model of promastigotes is generally used because it is able to mimic the conditions of the natural environment (i.e. the sand fly vector gut). However, infectivity decreases with culture passages and infection of laboratory animals is frequently required. Enrichment of the stationary phase population in highly infective metacyclic promastigotes is achieved by negative selection with peanut agglutinin (PNA), which is possible only in certain *Leishmania* species such as *L. major* and *L. infantum*. In this study, in vitro infectivity and differential gene expression of cultured PNA-negative promastigotes (Pro-PNA⁻) and metacyclic promastigotes isolated from the sand fly anterior thoracic midgut (Pro-Pper) have been compared.

Results: In vitro infectivity is about 30 % higher in terms of rate of infected cells and number of amastigotes per infected cell in Pro-Pper than in Pro-PNA⁻. This finding is in agreement with up-regulation of a leishmanolysin gene (gp63) and genes involved in biosynthesis of glycosylinositolphospholipids (GIPL), lipophosphoglycan (LPG) and proteophosphoglycan (PPG) in Pro-Pper. In addition, differences between Pro-Pper and Pro-PNA⁻ in genes involved in important cellular processes (e.g. signaling and regulation of gene expression) have been found.

(Continued on next page)

* Correspondence: pjalcolea@cib.csic.es

¹Laboratorio de Parasitología Molecular, Departamento de Microbiología Molecular y Biología de las Infecciones, Centro de Investigaciones Biológicas (Consejo Superior de Investigaciones Científicas), calle Ramiro de Maeztu, 9, 28040 Madrid, Spain

Full list of author information is available at the end of the article



(Continued from previous page)

Conclusions: Pro-Pper are significantly more infective than peanut lectin non-agglutinating ones. Therefore, negative selection with PNA is an appropriate method for isolating metacyclic promastigotes in stationary phase of axenic culture but it does not allow reaching the in vitro infectivity levels of Pro-Pper. Indeed, GIPL, LPG and PPG biosynthetic genes together with a gp63 gene are up-regulated in Pro-Pper and interestingly, the correlation coefficient between both transcriptomes in terms of transcript abundance is $R^2 = 0.68$. This means that the correlation is sufficiently high to consider that both samples are physiologically comparable (i.e. the experiment was correctly designed and performed) and sufficiently low to conclude that important differences in transcript abundance have been found. Therefore, the implications of axenic culture should be evaluated case-by-case in each experimental design even when the stationary phase population in culture is enriched in metacyclic promastigotes by negative selection with PNA.

Keywords: *Leishmania infantum*, Metacyclic promastigotes, *Phlebotomus perniciosus*, Peanut lectin agglutination, Infectivity, Differential gene expression

Background

Leishmaniasis is a neglected vector-borne parasitic disease caused by protozoan parasites grouped into the genus *Leishmania* (Kinetoplastida: Trypanosomatidae). The estimated prevalence is 12 million people worldwide. The most severe clinical manifestation is visceral leishmaniasis (VL), which is fatal without treatment. About 60,000 deaths by VL are declared annually [1, 2]. *L. infantum* is responsible for zoonotic VL in the Mediterranean basin and co-infection with HIV has been reported [3, 4]. Cutaneous and visceral signs are observed in the clinical profile of the canine reservoir. Recently, an outbreak in humans has been reported in central Spain, being hares reservoirs probably [5–7]. The life cycle of the parasite involves two stages: promastigotes and amastigotes. The promastigote is the fusiform motile extracellular stage with a flagellum emerging from the cellular body and the amastigote is the spherical immobile stage with a non-emergent flagellum. The developmental process of promastigotes is known as metacyclogenesis [8]. This process takes place within the gut of hematophagous sand flies (Diptera: Psychodidae, Phlebotominae), where different promastigote stages are observed (procyclics, haptomonads, nectomonads, leptomonads and metacyclics) [9]. When a sand fly vector feeds from a mammalian host, metacyclic promastigotes are injected in the dermis. Of those, few are internalized by phagocytes and differentiated to the amastigote stage under nitrosative stress, acidic pH, increased temperature and the activity of acid hydrolases. *Phlebotomus perniciosus* is the most common sand fly vector in the center and the West of the Mediterranean basin [10, 11].

Several proteins are anchored to the surface of promastigotes through glycosylphosphatidylinositol (GPI). The gp63 surface protein (leishmanolysin) is an important metalloprotease associated to resistance to lysis by the complement system [12]. Other major molecules anchored to the plasma membrane are the lipophosphoglycan (LPG),

the membrane-bound proteophosphoglycan (mPPG) and glycosylinositol phospholipids (GIPLs). It has been suggested that GIPLs protect the parasite against the hydrolytic enzymes of the parasitophorous vacuole (reviewed by [13]).

The sand fly gut is the natural microenvironment of promastigote differentiation to more infective non-proliferative metacyclic forms [14–16]. This process is often mimicked in vitro by axenization and culture at 26–27 °C in undefined media containing heat inactivated mammalian serum [17–22]. The main advantage of axenic cultures is that plenty of promastigote biomass is produced. However, attenuation of infectivity and virulence is observed across culture passages, which is often remedied by passages through laboratory animals (reviewed in [21]). Differences between promastigotes in culture and within the sand fly in terms of promastigote development to the amastigote stage were already reported [23, 24].

Sacks and Perkins [15] described that procyclic *L. major* promastigotes, located in the abdominal gut of the sand fly, were not infective. Conversely, metacyclic promastigotes, located in the anterior part of the thoracic midgut, were able to produce infection in mice. Metacyclogenesis also takes place in axenic culture [16, 25]. Isolation of metacyclic *L. major* and *L. infantum* promastigotes is performed in culture on the basis of differential agglutination properties with the *Arachys hypogaea* lectin, the peanut agglutinin (PNA). Procyclic promastigotes are able to agglutinate because the lectin binds to the galactose residues of the LPG. These residues are blocked by arabinose ones that are added in the ongoing of metacyclogenesis leading to the loss of the agglutination capability. A differential centrifugation procedure allows the isolation of agglutinating procyclic (Pro-PNA⁺) and non-agglutinating metacyclic (Pro-PNA⁻) promastigotes within the stationary phase of axenic culture. Agglutination is reversible because dilution of the suspension leads to disappearance of the agglutination complexes. For

this reason, additional PNA is required to maintain the appropriate concentration when the pellet is resuspended during the negative selection procedure of Pro-PNA⁻ [26]. Genes related with infectivity are up-regulated in the minor Pro-PNA⁻ promastigote subpopulation, which is more infective than the Pro-PNA⁺ in *L. infantum* [26], as well as in *L. major* [25, 27–29].

Transcriptome analysis of metacyclic promastigotes isolated from the gut of the sand fly (Pro-Pper) is possible thanks to mRNA amplification [23]. Comparative in vitro infection and high throughput transcriptome analyses of Pro-Pper versus Pro-PNA⁻ has been performed and their infectivity has been compared in vitro. Herein, we confirm that Pro-Pper metacyclic promastigotes are more infective than Pro-PNA⁻.

Methods

Ethics statement

Blood samples were extracted from a New Zealand White rabbit to feed *P. perniciosus* sand flies during infection with a suspension of phagocytic cells infected with *L. infantum*. The protocol was performed according to the EU (2010/63) and Spain (RD1201/2005) regulations and it was approved by the ISCIII Ethics Committee for Research in Animal Welfare (license CBA PA73-2011).

Promastigote axenic culture

Promastigotes of the MCAN/ES/98/10445 isolate (zymodeme MON-1) of *Leishmania infantum* were cultured at 27 °C in RPMI 1640 supplemented with L-glutamine (Lonza-Cambrex, Karlskoga, Sweden), 10 % heat inactivated fetal bovine serum (HIFBS) (Lonza-Cambrex) and 100 µg/ml streptomycin – 100 IU/ml penicillin (Lonza-Cambrex). The inocula were used at the 5th passage after they had been obtained from the sand fly gut [23].

Negative selection of metacyclic promastigotes with PNA

Stationary phase promastigotes were harvested at 2,000 g for 10 min and resuspended at a cell density of 2×10^8 cells/ml in 10 ml complete medium containing 50 µg/ml PNA [30]. Promastigotes were allowed to agglutinate at room temperature for 30 min. Then, the sediment and the supernatant were recovered. The former was diluted to the initial volume in fresh complete medium containing 50 µg/ml PNA. Both fractions were centrifuged at 200 g for 10 min and the supernatants obtained were centrifuged at 2,000 g to obtain PNA⁻ promastigotes (Pro-PNA⁻). All steps were checked at the light microscope.

In vitro infection of the human U937 myeloid cell line

The human cell line U937 (ATCC® CRL1593.2), originally obtained from a patient with histiocytic leukemia [31], was infected in vitro with *L. infantum* promastigotes for

two different purposes: infection of sand flies to obtain promastigotes from the stomodeal valve (Pro-Pper) and evaluation of in vitro infectivity of Pro-PNA⁻ and Pro-Pper. First, the U937 cell line was cultured at 37 °C in complete medium in the presence of 5 % CO₂ for 72 h. Then, the cells were centrifuged at 250 g and differentiated in complete medium by stimulation with 20 ng/ml phorbol 12-myristate 13-acetate (Sigma, Saint Louis, MO) for 72 h [32]. This step was performed in a 175 cm² flask when the resulting infected U937 cells were diluted in rabbit blood to infect sand flies experimentally (see below). In the case of evaluation of the in vitro infection capability of promastigotes, infections of U937 cells were performed over 8-well cell chamber slides (LabTek, New York, NY). The cultures were mildly rinsed with RPMI supplemented with L-glutamine (Lonza-Cambrex). Only, cells cultured in flasks were detached by vigorous shaking in the presence of 0.5 g/l trypsin, 0.2 g/l EDTA (Lonza-Cambrex). Trypsin was inactivated by adding one volume of complete medium. The differentiated cells were recovered by centrifugation. Then, they were mixed with stationary phase promastigotes at a promastigote:cell ratio 20:1 and incubated at 37 °C in complete medium in a water bath for 2 h. The mixture was mildly mixed every 15 min. Once this incubation step was over, the cells were harvested and incubated again in the culture flasks in complete medium at 37 °C, in an atmosphere of 5 % CO₂ for 72 h. The cultures were rinsed with complete medium after 2 h and 16 h. Infections were checked at the light microscope with Giemsa stain prior to sand fly feeding. In the case of differentiated cells attached to the 8-well chamber slides, infections were performed at 37 °C at a promastigote:cell ratio 5:1 in 400 µl complete medium in an atmosphere of 5 % CO₂ for 2 h. Next, the cells were rinsed with complete medium at 2 and 16 h post-infection as in the previous procedure. The incubations were resumed and samples were taken at 24, 48 and 96 h post-infection to estimate the percentage of infected cells and the number of amastigotes per infected cell (100 cells were counted per sample). For this purpose, three more washes were performed prior to treatment with hypotonic solution (180 µl complete medium diluted with 220 µl water per well) for 5 min. Four washes with 150 µl ethanol-acetic acid 3:1 were carried out once the hypotonic solution had been removed. Then, fixation was performed with the same solution for 10 min and this step was repeated three times. Finally, cells were allowed to air dry and the wells removed from the slide. Modified Giemsa staining was performed with Diff-Quick® Stain Solution I and II (Dade Behring, Marburg, Germany). The preparations were washed with distilled water, air dried and mounted with Entellan® Neu (Merck, Darmstadt, Germany). The percentage of infected cells and the number of amastigotes per infected cell were estimated in three biological

replicate experiments and the statistical analysis was based on the Student's paired t-test.

Infection of *P. perniciosus* and isolation of metacyclic promastigotes from the stomodeal valve

An established colony of *P. perniciosus* sand flies [33] was maintained in a climatic chamber at 27–28 °C, 90–100 % relative humidity, 17 h light - 7 h darkness photoperiod in the presence of a 30 % fructose solution. About 150–200 sand flies were fed with a suspension of 2×10^6 infected U937 cells in 2 ml of defibrinated rabbit blood over a chicken skin membrane [34]. Sand fly samples were dissected daily in order to follow the course of infection. After 5 days, sand flies were dissected daily with the additional purpose of extracting the guts for isolation of mature promastigotes from the anterior thoracic midgut close to the stomodeal valve (Fig. 1) and subsequent preparation of RNA samples (see below). For this purpose, the gut was dissected to isolate the anterior part of the thoracic midgut and recover promastigotes in PBS with a Pasteur pipette. Three independent samples were prepared. Each one included promastigotes from about 20 infected sand flies. The replicate samples finally used had been obtained the day before the death phase started (day 6). This was also applicable for the equivalent Pro-PNA⁻ population (see above).




Fig. 1 Isolation of Pro-Pper. Promastigotes within the stomodeal valve of *P. perniciosus*. Sand flies were dissected and the guts separated. The abdominal gut and the posterior part of the thoracic midgut were discarded and Pro-Pper were recovered from the anterior part of the thoracic midgut (discontinuous line). The Pro-Pper population is enriched in metacyclic promastigotes as they are near the stomodeal valve (SV). Carryover of leptomonads was minimized by recovering just promastigotes in suspension and avoiding gut tissue as much as possible. However, it is assumed that this population is heterogeneous as expected in any biological experiment, as well as the Pro-PNA⁻ population

RNA isolation, mRNA amplification and synthesis of labeled cDNA

Total RNA was purified from Pro-Pper and Pro-PNA⁻ with TRIzol[®] reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. One μg per ml of glycogen (Life Technologies) was added as carrier to the aqueous phase just before isopropanol precipitation. mRNA was doubly amplified (aaRNA) using MessageAmp[™] II aRNA Amplification Kit (Life Technologies) as previously described [24]. RNA quality was assessed with the Agilent 2100 Bioanalyzer (Life Technologies) in an RNA 6000 NanoChip according to the manufacturer's instructions.

The first strand aminoallyl-cDNA was synthesized using 10 μg aaRNA template. First, aaRNA was mixed with 6 μg of random hexamer primers (Life Technologies). The mixture was denatured at 70 °C for 10 min and immediately cooled. Then, first strand synthesis was performed at 46 °C in 30 μl final reaction volume for 3 h with 570 μM dATP, dCTP and dGTP, 230 μM dTTP, 340 μM aminoallyl-dUTP, 10 μM DTT and 600 U SuperScript[®] Reverse Transcriptase (Life Technologies). Next, RNA was degraded at 70 °C in 100 mM NaOH/10 mM EDTA for 30 min and the solution was then neutralized with 3 μl of 3 M sodium acetate pH5.2. Aminoallyl-cDNA was purified with QiaQuick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions except for two buffers: custom phosphate wash (5 mM KPO₄, 80 % ethanol, pH8.0) and phosphate elution (4 mM KPO₄) buffers replaced those provided in the kit to avoid blockage of the amino group. Purified aminoallyl-cDNA was completely dried in a vacuum centrifuge and resuspended in 10 μl of water. A solution containing the cyanine monofunctional dyes (Cy3 and Cy5; GE Healthcare, Chalfont Saint Giles, UK) were prepared at 12 ng/ μl in DMSO. Coupling was allowed at room temperature in darkness for 1 h once 5 μl of the Cy3 or Cy5 solution was added to the respective samples (Cy3 for Pro-PNA⁻ and Cy5 for Pro-Pper). Finally, labelled cDNA was purified with QiaQuick PCR Purification Kit (Qiagen) according to the manufacturer's instructions.

Microarray hybridization analysis of differential gene expression

L. infantum shotgun genome microarrays [26] were washed in 0.1 % N-lauroylsarcosine in 2X SSC, then in 2X SSC. The slides were heated at 95 °C for 3 min and immediately chilled in 100 % ethanol (10 s after removal from boiling water) thus denaturing and fixing DNA. The slide was spin dried in a minicentrifuge and attached upside down over a Hybri-Slip coverslip (Sigma) containing a 60 μl drop of 3X SSC, 0.3 % N-lauroylsarcosine, 60 mM Tris-HCl pH8.0, 83 ng/ml denatured

herring sperm DNA and 1 % BSA. Blocking was allowed at 42 °C for 30 min using a hybridization chamber submerged in a water bath. Then, blocked microarrays were incubated at 40 °C for 16 h with a mixture of the Cy3- and Cy5-labelled cDNA samples (50 pmol dye each) in hybridization solution (equal to blocking solution except for 0.1 % BSA, 25 ng/ml poly(T) and 50 % deionized formamide). The slide was washed three times, first in 2X SSC, 0.2 % SDS at 40 °C, then in 1X SSC at room temperature and finally in 0.2X SSC at room temperature.

Hybridized microarrays were scanned with GenePix 4100A (Axon, Foster City, CA). Local feature background was subtracted from raw fluorescence intensity values with GenePix Pro 7.0 software. Raw data were normalized by the LOWESS per pin algorithm and Student's t-test contrast considering three biological replicates was performed with AlmaZen software (BioAlma, Tres Cantos, Spain). Differential expression cutoff values were applied to obtain the set of clones containing differentially regulated genes: (i) fold change $F \geq 2$ (Cy5/Cy3 ratio if $Cy5 > Cy3$) or $F \leq -2$ ($-Cy3/Cy5$ ratio if $Cy3 > Cy5$), (ii) total relative fluorescence intensity value > 5000 arbitrary fluorescence units and (iii) $p^* < 0.05$. The clones selected on the basis of these conditions were grown and sequenced with the M13-pUC18 primers and assembled as described [26]. These clones were classified according to the following genome alignment outcomes: (i) e-value $< 1e-10$ for both ends, (ii) convergent orientation in the genome sequence and (iii) clone length ≤ 11 kbp [26]. Type *a* clones were defined by a unique pair of alignments. Type *b* clones presented more than a pair of alignments due to adjoining sequence repeats; the best sequence identity is considered in this case. Finally, *c* clones did not completely fulfill all three requirements, which is mostly due to the presence of two or more inserts in the clone or the lack of one of the end sequences. Clones were then associated to annotated genes using a Perl script.

Real time quantitative RT-PCR (qRT-PCR)

Synthesis of unlabeled single stranded cDNA was performed as indicated above except for the dNTP mixture (10 mM each dATP, dCTP, dGTP and dTTP in this case). The design of primers and FAM-MGB probes (Additional file 1: Table S1), configuration of 384-well plates and in situ synthesis was managed by Custom TaqMan® Assays-by-Design (Life Technologies). The qRT-PCR assays were run in a 7900HT Fast Real Time PCR system (Life Technologies) once cDNA templates and TaqMan® Universal Master Mix (Life Technologies) were added. Three sample replicates and three 1/10 dilutions of each one were included (25, 2.5 and 0.25 ng cDNA in 15 µl final reaction volume). Thermal cycling conditions were: 95 °C for 5 min; 40 x [95 °C for 30s; 60 °C for 1 min, data acquisition]. A 20 %

coefficient of variation cutoff was applied and PCR efficiencies were calculated by the standard curve best fit method [35]. Normalized quantities (Q_n) were calculated by dividing the efficiency-corrected raw quantity values (equal to efficiency to the power of $-Ct$) of the gene of interest by those of the reference gene (*L. infantum* gGAPDH). Then, F was obtained by dividing Q_n of both experimental conditions (Pro-Pper/Pro-PNA⁻) for each dilution. The mean F value and the SD were calculated considering Q_n values of all dilutions.

Results and discussion

Isolation of Pro-Pper and evaluation of in vitro infection

In 1985, it was described that *L. major* PNA⁻ promastigotes are more infective than PNA⁺ [27]. This was corroborated in *L. infantum* by us and up-regulated genes involved in infectivity were found [26]. In this study, Pro-Pper and Pro-PNA⁻ have been compared in terms of in vitro infectivity and differential gene expression.

Digestive tracts were obtained from sand flies once they were dissected. The anterior thoracic midgut was selected (Fig. 1). Then, Pro-Pper promastigotes in suspension were recovered and carryover of gut tissue (and therefore leptomonads) was minimized. Three biological replicates of the experiments were performed. Pro-Pper samples obtained for evaluation of in vitro infection of U937 cells were recovered in PBS and immediately resuspended in 200 µl complete medium. The suspension was added to PMA-differentiated U937 cells attached to 8-well slides and allowed to infect. After 2 h at 37 °C, 5 % CO₂, the culture was washed to eliminate remaining promastigotes. Finally, samples were obtained at 24, 48 and 96 h post-infection. The same procedure was followed for Pro-PNA⁻. Then, the percentage of infected cells and the number of amastigotes per infected cell were estimated. Statistical analysis was performed by the unpaired Student's t test. The reduction of in vitro infectivity in Pro-PNA⁻ with respect to Pro-Pper in terms of rate of infected cells is 38, 22 and 22 % at 24, 48 and 96 h post-infection, respectively (Fig. 2a). The reduction in terms of average number of amastigotes per infected cell is 35, 25 and 33 % at 24, 48 and 96 h post-infection, respectively (Fig. 2b). The differences were statistically significant in all cases ($p < 0.001$). Therefore, culture reduces the infection ability of promastigotes even when metacyclics are obtained by negative selection with PNA. Hence, this procedure is an appropriate method for isolation of metacyclics in culture but worse than isolation from the natural environment, i.e. the sand fly anterior thoracic midgut (Fig. 2).

Transcript amplification and microarray hybridization analysis

Pro-Pper samples used for gene expression analysis were immediately washed once in PBS and resuspended in




Fig. 2 In vitro infection of the stimulated U937 cell line with Pro-PNA⁻ and Pro-Pper. All differences are statistically significant (unpaired Student's t-test, $p < 0.001$). **a** Infection rate (%). Mean \pm SD (Pro-PNA⁻ and Pro-Pper, respectively): 13 ± 2 and 21 ± 1 (24 h); 33 ± 3 and 42 ± 1 (48 h); 35 ± 3 and 45 ± 1 (96 h). **b** Number of amastigotes per infected cell. Mean \pm SD (Pro-PNA⁻ and Pro-Pper, respectively): 2.1 ± 0.3 and 3.2 ± 0.0 (24 h); 5.3 ± 0.5 and 7.0 ± 0.1 (48 h); 6.0 ± 1 and 9 ± 1 (96 h)

TRIZOL[®] reagent (Life Technologies). Then, two rounds of mRNA amplification were performed to obtain enough material for the high-throughput gene expression analysis. Obviously, Pro-PNA⁻ sample processing was the same.

Several genes had been included in the microarrays as positive hybridization controls [26]. The stage-specific A2 amastigote gene [36] is not differentially expressed between Pro-Pper and Pro-PNA⁻ (Additional file 2: Table S2) as expected. The fluorescence intensity values (FI) of all negative microarray hybridization controls are below the average background level as expected (Additional file 2: Table S2). The origin of these genes is the extremophile *Leptospirillum ferrooxidans* [26]. In total, 174 differentially regulated genes have been found: 111 are up-regulated in Pro-Pper and 63 in Pro-PNA⁻ (Fig. 3, Tables 1 and 2,

Additional file 3: Tables S3-S5). The Pearson correlation coefficient between Pro-PNA⁻ and Pro-Pper in terms of normalized fluorescence intensity values is $R^2 = 0.68$ (Fig. 3).

qRT-PCR analysis

Most clones overlapping with more than one gene annotation were analyzed by the TaqMan Probe qRT-PCR approach. Therefore, large clones that represent more than one CDS could be resolved. This approach was also useful to validate 26.3 % of the microarray results (Tables 2 and 3), together with the internal hybridization controls already mentioned (Additional file 2: Table S2). Constant expression values were obtained just in the case of certain clones overlapping with more than one gene.




Fig. 3 M/A scatter plot of the three-replicate Pro-Pper/Pro-PNA⁻ microarray hybridization experiment. $M = (\log_2 R_i - \log_2 G_i)$ and $A = [(\log_2 R_i + \log_2 G_i)/2]$, where R and G are, respectively, red (Cy5) and green (Cy3) fluorescence intensity values. Red spots represent selected clones that contain a gene up-regulated by at least 2-fold and green spots represent those down-regulated by at least 2-fold. The Pearson correlation coefficient (R^2) is provided

Table 1 Absolute frequencies of differentially regulated genes in Pro-Pper/Pro-PNA⁻

Annotation status	Frequency of differentially regulated genes in Pro-Pper/Pro-PNA ⁻	
	Up-regulated	Down-regulated
Genes of known function	53	26
Hypothetical protein genes	56	31
Type c clones	2	6
Total (n = 174)	111	63

Differential gene expression between Pro-Pper and Pro-PNA⁻

In a study of differentiation of promastigotes to amastigotes, Lahav et al. [37] described that relative transcript levels do not correspond with abundance of the encoded protein in many cases. Indeed, coincidence was observed in just about 25 % cases in quantitative terms (Pearson correlation coefficient). However, qualitative coincidences (constitutive expression, up-regulation and down-regulation) were observed in 65 % cases (589 out of 902 genes). As we have seen, one of the purposes of this study is comparing Pro-PNA⁻ and Pro-Pper in terms of relative transcript abundance, focusing on differentially regulated genes. For this purpose, the qualitative information is more relevant than the quantitative because it provides a picture of the steady-state transcript levels in both conditions. Hence, insight into the adequacy of negative selection of metacyclics in culture with PNA compared to the natural environment (the sand fly gut) is provided herein. Additionally, the different approaches used (e.g. microarray hybridization analysis and qRT-PCR in this study) have different dynamic ranges and sometimes provide different quantitative results for coincident qualitative results. In conclusion, the transcriptome analysis is useful in this study and it is the only possibility to study gene expression in Pro-Pper so far. In fact, the negligible amount of parasite material obtained from sand fly dissections does not allow performing analysis of individual proteins and the proteome, whereas it is possible to amplify RNA. In our case, 174 genes are differentially regulated between Pro-PNA⁻ and Pro-Pper. Therefore, we expect about 113 genes showing the same qualitative outcome of relative abundance at the transcript and protein levels.

The comprehensive study of the differences found in transcript abundance is illustrated in Fig. 4. The most striking qPCR results are illustrated in Fig. 5. Provided that unequivocal identification is very important [38], gene name abbreviations have been included in Tables 2 and 3. Unless otherwise indicated, the term up-regulation refers to Pro-Pper and down-regulation to Pro-PNA⁻.

Chromatin structure, nucleocytoplasmic transport and regulation of gene expression at the post-transcriptional and post-translational levels

Three up-regulated genes in Pro-Pper involved in DNA replication and chromatin remodeling have been found: histone (H3), SNF2/RAD54 helicase and minichromosome maintenance protein (mcm). Metacyclic promastigotes are non-dividing forms of the parasite, but H3 gene over-expression is in agreement with independence of mRNA levels from DNA synthesis [39].

A nuclear movement protein gene (NUDC) is up-regulated in Pro-Pper, whereas two major vault protein genes (MVP) are down-regulated. This suggests differences in nucleocytoplasmic transport and signaling between Pro-Pper and Pro-PNA⁻. In fact, MVPs are the main constituents of vaults, which are protein complexes that may participate in both processes [40] and they are able to interact with the target of rapamycin protein 4 (TOR4) in *Trypanosoma brucei* [41].

A transcription factor-like protein gene (TF-like) and the RNA helicase LinJ.15.0130 are up-regulated in Pro-Pper. As for translation regulation, several genes are differentially regulated between both populations of metacyclics. On the one hand, the elongation factor 1 β (EF1 β), the initiation factor 2 (IF2), the 40S ribosomal proteins S8, S19 and S30, the 60S ribosomal proteins L14, L36 and L37a and the glycyl-tRNA synthetase are up-regulated. On the other hand, the diphthine synthase gene, the ribosomal proteins S2 and L3 are down-regulated. The EF1 β is up-regulated by cadmium [42], whereas the IF2 is up-regulated in stationary phase promastigotes with respect to intracellular amastigotes [24]. Diphthine is the direct precursor of diphthamine, a molecule able to inactivate the IF2 by addition of a residue of ADP-ribose, as the diphtheria toxin does [43]. Down-regulation of the diphthine synthase (DpS) in Pro-Pper (Table 3) is in agreement with up-regulation of the IF2. Finally, the cyclophilin genes CYP3 and CYP11, involved in protein folding, are up-regulated.

Proteolysis

The oligopeptidase B gene (OPB) is up-regulated in Pro-Pper, whereas the calpain-like cysteine peptidase (C2Cp) LinJ.31.0480 is down-regulated. The results found also suggest changes in ubiquitin-proteasome protein degradation pathway between Pro-Pper and Pro-PNA⁻, as the ubiquitin activating enzyme E1 gene (UbqA-E1), the E3 activating protein cullin and the ubiquitin hydrolase (UbH) are up-regulated.

Protein-protein interaction

A leucine-rich repeat protein (LRRP) of unknown function in the parasite is up-regulated in Pro-PNA⁻. LRRPs have been associated to functions generally involving

Table 2 Genes of known function up-regulated in Pro-Pper/Pro-PNA⁻

Clone	F	Log ₂ F ±SD	p	e-value		Def.	TriTrypDB Id.	Annotated gene function	qRT-PCR	
				Fw	Rv				F ±SD	
Lin85D8	3.07	1.6 ± 0.1	0.047	0	0	b	LinJ.08.0680 LinJ.08.0690	Amastin-like protein Amastin-like protein	+	2.5 ± 0.1 2.5 ± 0.1
Lin86D3	8.13	3.0 ± 0.2	0.000	0	9e-37	b	LinJ.15.0130	ATP-dependent RNA helicase, putative	N.D.	
Lin89E3	3.35	1.7 ± 0.2	0.044	7e-96	0	b	LinJ.08.1320	Amastin-like protein	+	2.5 ± 0.1
Lin88E3	2.20	1.1 ± 0.2	0.002	0	0	b	LinJ.21.1670	2-oxoisovalerate deshydrogenase α subunit, putative (KIVDH)	N.D.	
Lin96C1	2.88	1.5 ± 0.4	0.009	0	0	b	LinJ.11.0060	Protein kinase, putative (PK)	N.D.	
Lin100B12	4.88	2.3 ± 0.4	0.021	0	0	b	LinJ.06.0340 LinJ.06.0350 LinJ.06.0360	Oligopeptidase B/Ser peptidase Clan SC family S19A (OPB) NAD(P)-dependent steroid dehydrogenase Hypothetical protein, conserved	+	312 ± 25 1.1 ± 25
Lin121C6	2.68	1.4 ± 0.6	0.006	0	0	b	LinJ.28.0940	Minichromosome maintenance complex protein putative (mme)	N.D.	
Lin142C8	3.28	1.7 ± 0.4	0.025	0	0	a	LinJ.21.0790 LinJ.21.0800	Hypothetical protein, conserved 60S ribosomal protein L36, putative	+	13.8 ± 1.3
Lin143C12	2.24	1.2 ± 0.7	0.004	0	0	b	LinJ.21.0810 LinJ.21.0820	Hypothetical protein, conserved ATPase subunit 9, putative (ATPau.9)	+	8.4 ± 0.2
Lin145A1	3.55	1.8 ± 0.3	0.009	0	0	b	LinJ.22.1360 LinJ.22.1370 LinJ.30.0690 LinJ.30.0700 LinJ.30.0710 LinJ.30.0720	Hypothetical protein, unknown function Ribosomal protein 40S L14, putative 40S ribosomal protein S30, putative 40S ribosomal protein S30, putative 40S ribosomal protein S30, putative Nuclear movement protein NUDC (NUDC)	+	2.0 ± 0.0 69.5 ± 2.1 69.5 ± 2.1 69.5 ± 2.1 5.6 ± 0.4
Lin146A12	3.07	1.6 ± 0.3	0.003	0	0	b	LinJ.30.0690 LinJ.30.0700 LinJ.30.0710 LinJ.30.0720	40S ribosomal protein S30, putative 40S ribosomal protein S30, putative 40S ribosomal protein S30, putative Nuclear movement protein NUDC (NUDC)	+	69.5 ± 2.1 69.5 ± 2.1 69.5 ± 2.1 5.6 ± 0.4
Lin151C7	2.01	1.0 ± 0.3	0.026	0	0	b	LinJ.27.1170 LinJ.27.1180	Ubiquitin hydrolase/cysteine peptidase, Clan CA, family C19, putative (UbjH) Hypothetical protein, conserved	+	135 ± 12
Lin155B1	2.29	1.2 ± 0.2	0.033	0	0	b	LinJ.05.1210	Surface antigen-like protein (SALp2)	N.D.	
Lin158C1	2.82	1.5 ± 0.1	0.004	0	0	b	LinJ.21.2140	F1 ATP synthase, subunit γ, putative (F1γ)	N.D.	
Lin159D8	2.76	1.5 ± 0.8	0.016	0	0	b	LinJ.36.4370 LinJ.36.4380	Hypothetical protein, conserved Oxidoreductase, putative (OXR)	+	11.8 ± 0.3
Lin169A11	3.89	2.0 ± 0.2	0.014	0	0	a	LinJ.23.0630 LinJ.23.0640	Oxidoreductase-like protein (OXR) Hypothetical protein, conserved	+	233 ± 7
Lin169G11	2.35	1.2 ± 0.1	0.039	0	0	b	LinJ.26.0050 LinJ.26.0060	Protein kinase, putative (PK) Hypothetical protein, conserved	+	100 ± 15
Lin169E6	2.85	1.5 ± 0.3	0.015	0	0	b	LinJ.32.0550	Profilin, putative	N.D.	
Lin170B7	2.67	1.4 ± 0.9	0.033	0	0	a	LinJ.23.0860	3-ketoacyl-CoA thiolase-like protein (ACAT)	N.D.	
Lin175D9	2.84	1.5 ± 0.5	0.018	5e-63	4e-57	a	LinJ.31.2040	Glycoprotein 63-like protein gp63 (leishmanolysin) /metallopeptidase Clan MA(M), family M8 (gp63)	N.D.	
Lin177E10	3.50	1.8 ± 0.1	0.021	0	0	b	LinJ.16.0600	Histone H3, putative (H3)	N.D.	
Lin177F8	2.14	1.1 ± 0.1	0.032	0	0	a	LinJ.29.0020	Transcription factor-like protein (TF-like)	N.D.	
Lin178A5	2.74	1.4 ± 0.5	0.011	0	0	b	LinJ.36.1490	Elongation factor 1β, putative (EF1β)	N.D.	
Lin179C9	3.42	1.8 ± 0.3	0.039	0	0	b	LinJ.23.0140	Cyclophilin-like peptidyl-prolyl cis-trans isomerase, putative (CYP3)	N.D.	
Lin179E10	3.58	1.8 ± 0.3	0.042	0	0	b	LinJ.31.2350	ADP-ribosylation factor (ARF)	+	22.1 ± 0.6
Lin185G7	5.56	2.4 ± 0.4	0.008	2 e-28	1 e-11	a	LinJ.31.2360 LinJ.18.0360	Phosphatidylethanolamine N-methyltransferase-like protein GPI transamidase subunit 8, cysteine peptidase, ClanAD, family C13, putative (GPIT.8)	-	1.5 ± 0.3 342 ± 15
Lin187C5	3.99	2.0 ± 0.3	0.028	0	0	b	LinJ.11.0040 LinJ.11.0050	ABC transporter, putative SNF2/RAD54-related DNA helicase, putative (SNF2/RAD54)	+	9.7 ± 0.2 323 ± 49
Lin187C7	2.54	1.3 ± 0.3	0.040	0	0	b	LinJ.26.1680 LinJ.26.1690 LinJ.26.1700	Sphingolipid 84-desaturase, putative (DECS) Cytochrome c oxidase, subunit V (COXV), putative Hypothetical protein, conserved	+	3.3 ± 0.2 -1.4 ± 0.2
Lin187C10	4.78	2.3 ± 0.4	0.006	0	0	b	LinJ.06.1320	Pteridine transporter, putative (PT)	N.D.	
Lin188B1	2.50	1.3 ± 0.1	0.044	0	0	a	LinJ.31.1600	Cytochrome c oxidase, subunit VIII, putative (COXVIII)	+	2.1 ± 0.2
Lin188C9	2.11	1.1 ± 0.6	0.000	0	0	a	LinJ.31.1610 LinJ.36.4030	Hypothetical protein, conserved Glycyl-RNA synthetase, putative	N.D.	
Lin189B12	2.24	1.2 ± 0.2	0.029	0	0	a	LinJ.24.1370 LinJ.24.1380	Hypothetical protein, conserved Translation initiation factor 2, putative (IF2)	+	2.7 ± 0.3
Lin196B3	2.28	1.2 ± 0.1	0.003	0	0	b	LinJ.28.0850	Dual-specificity protein phosphatase, putative (DualPP)	N.D.	
Lin202E4	3.40	1.8 ± 0.8	0.000	0	0	b	LinJ.29.1950	Dihydroliopamide dehydrogenase, putative (DHLHDH)	N.D.	
Lin208F7	3.07	1.6 ± 1.1	0.038	0	0	b	LinJ.30.3640	Serine/threonine protein kinase, putative (PK)	N.D.	
Lin212G5	2.09	1.1 ± 0.3	0.009	0	0	b	LinJ.34.0840	Serine/threonine protein phosphatase 1, putative (PP1)	N.D.	
Lin215A7	2.68	1.4 ± .56	0.006	0	0	a	LinJ.32.0710 LinJ.32.0720	OSM3-like kinesin, putative (OSM3) Hypothetical protein, conserved	+	15 ± 1
Lin220A9	5.42	2.4 ± 0.5	0.013	0	0	a	LinJ.24.1380	Translation initiation factor 2, putative (IF2)	+	2.7 ± 0.3
Lin221G3	2.28	1.2 ± 0.4	0.035	0	0	b	LinJ.36.6360 LinJ.36.6370	Hypothetical protein, conserved Centrin, putative (CETN)	+	7.5 ± 0.7
Lin232G3	2.35	1.2 ± 0.4	0.029	2e-74	5e-72	a	LinJ.21.1590	ATP synthase, putative	N.D.	
Lin240D3	3.51	1.8 ± 0.7	0.039	0	0	c	LinJ.35.3970 LinJ.29.0940 LinJ.29.0950	Hypothetical protein, conserved Hypothetical protein, conserved ADP-ribosylation factor 3, putative (ARF3)	+	22 ± 1
Lin250G8	2.91	1.5 ± 0.4	0.049	0	0	b	LinJ.36.6670 LinJ.36.6680	Methylentetrahydrofolate reductase, putative 40S ribosomal protein S8, putative	-	-1.2 ± 0.3 5.2 ± 0.3
Lin255D9	3.15	1.7 ± 0.6	0.004	6e-112	2e-111	a	LinJ.23.1400	Coronin, putative	N.D.	
Lin267E5	2.30	1.2 ± 0.5	0.046	0	0	a	LinJ.14.1500	Phosphoglycan β1.3-galactosyltransferase, putative (PG-β-1,3-GalT)	N.D.	
Lin272A3	3.49	1.8 ± 0.2	0.036	0	0	b	LinJ.23.0040 LinJ.23.0050	β-propeller protein, putative Peroxisomal/trypanoxin peroxidase, putative	-	-1.4 ± 0.2 -1.2 ± 0.2
Lin288H7	3.19	1.7 ± 1.1	0.049	0	0	b	LinJ.23.0060 LinJ.34.2610	Cyclophilin, putative (CYP11) Calcineurin-like serine/threonine protein phosphatase/phosphoesterase	+	2.1 ± 0.2 -1.2 ± 0.0
Lin289A8	2.56	1.3 ± 0.5	0.034	0	0	b	LinJ.34.2620	Ribosomal protein S19, putative	+	2.3 ± 0.1
Lin292G5	3.57	1.8 ± 0.8	0.000	0	0	a	LinJ.07.0010 LinJ.17.1460 LinJ.17.1470	Ubiquitin-activating enzyme E1, putative (UbjA-E1) Hypothetical protein, conserved L-gluconolactone oxidase, putative	N.D. N.D. +	
Lin296F4	-2.14	-1.1 ± 0.2	0.032	0	0	b	LinJ.20.0790 LinJ.20.0800	Hypothetical protein, conserved Tubulin tyrosine ligase, putative (TubTyrL)	+	9.2 ± 0.6 346 ± 44
Lin302E4	3.12	1.6 ± 0.4	0.002	0	0	a	LinJ.36.2080 LinJ.36.2090	Hypothetical protein, conserved Serine/threonine protein phosphatase 2B, catalytic subunit A2, putative (PP2B-A2)	+	2.3 ± 0.1
Lin308A8	2.62	1.4 ± 0.4	0.038	0	0	b	LinJ.30.0700 LinJ.30.0710 LinJ.30.0720	40S ribosomal protein S30, putative 40S ribosomal protein S30, putative Nuclear movement protein NUDC (NUDC)	+	69.5 ± 2.1 69.5 ± 2.1 5.6 ± 0.3
Lin312F4	5.31	2.4 ± 0.4	0.034	0	1e-82	b	LinJ.21.2180 LinJ.21.2190 LinJ.21.2200	GPI transamidase GAA1 component, putative (GPIT-GAA1) 60S ribosomal protein L37a, putative 20S proteasome α5 subunit, putative	+	3.0 ± 0.1 3.0 ± 0.4 -1.8 ± 0.3

Features described: clone number, fold change (up-regulation if $F \geq 2.0$), $\log_2 F$ and standard deviation (SD), Student's t-test p-value (p), clone definition (Def.; see Methods), TriTrypDB identifier, annotated gene function (including abbreviations defined in the text) and qRT-PCR outcome. Genes in grey (clones that overlap with more than one annotated gene): they are not differentially regulated (confirmed by qRT-PCR) or there is no evidence to support that they are differentially regulated in other cases (not determined by qRT-PCR)

Table 3 Genes of known function down-regulated in Pro-Pper/Pro-PNA⁻

Clone	F	Log ₂ F ±SD	p	e-value		Def.	TriTrypDB Id.	Annotated gene function	qRT-PCR	
				Fw	Rv				F	SD
Lin85F11	-2.67	-1.4 ± 0.2	0.040	1e-156	2e-158	a	LinJ.34.4160	Phosphatidylinositol 3-kinase-like protein (TOR2)	N.D.	
Lin105H12	-2.04	-1.0 ± 0.1	0.012	0	0	a	LinJ.27.1700	Protein kinase-like protein (PK)	N.D.	
Lin106G6	-2.87	-1.5 ± 1.2	0.021	0	0	a	LinJ.32.0460	40S ribosomal subunit S2, putative	+	-2.2 ± 0.3
Lin110G8	-2.02	-1.0 ± 0.2	0.013	0	0	b	LinJ.32.0470 LinJ.31.0480	Prostaglandin F synthase, putative Calpain-like cysteine peptidase, Clan CA. family C2, putative (C2cp)	N.D.	-1.2 ± 0.1
Lin125H7	-2.04	-1.0 ± 0.2	0.035	0	0	b	LinJ.28.3110	Dynein-light chain, putative (DymLC)	N.D.	
Lin139A6	-2.32	-1.2 ± 0.4	0.008	6e-158	6e-81	b	LinJ.02.0100	Phosphatidylinositol 3-kinase-like protein (PI3K)	N.D.	
Lin144A12	-2.31	-1.2 ± 0.3	0.029	0	0	a	LinJ.15.0800	ATP-binding cassette 1-like protein (ABC1)	N.D.	
Lin148A8	-2.17	-1.1 ± 0.6	0.042	0	0	b	LinJ.21.0720	Nucleotide-binding protein, putative (NBP-MRP)	+	-7.9 ± 0.1
Lin166E5	-2.11	-1.1 ± 0.6	0.030	0	0	b	LinJ.21.0730	Metallo-β-lactamase family protein, putative	-	1.1 ± 0.3
Lin167D1	-2.38	-1.2 ± 0.2	0.037	0	0	b	LinJ.20.0970	Protein kinase, putative (PK)	N.D.	
Lin172C3	-2.23	-1.1 ± 0.2	0.007	2e-71	6e-75	a	LinJ.04.0470	ADP-ribosylation factor, putative (ARF)	N.D.	
Lin185G3	-2.45	-1.3 ± 0.2	0.028	0	0	a	LinJ.21.0260	Major vault protein (MVP)	N.D.	
Lin182D9	-2.28	-1.2 ± 0.1	0.034	0	0	b	LinJ.06.0860	Lipin, putative	N.D.	
Lin188B3	-2.69	-1.4 ± 0.3	0.031	0	0	b	LinJ.30.3230	3-hydroxy-3-methylglutaryl-CoA reductase, putative (HMGCR)	N.D.	
Lin197G1	-2.18	-1.1 ± 0.1	0.004	0	0	b	LinJ.05.0060	Major vault protein, putative (MVP)	N.D.	
Lin209G10	-3.80	-1.9 ± 0.6	0.027	1e-60	5e-63	b	LinJ.34.2730	Ribosomal protein L3, putative	N.D.	
Lin221E12	-2.18	-1.1 ± 0.3	0.049	0	0	a	LinJ.09.0580	Leucine-rich repeat protein, putative (LRRP)	N.D.	
Lin228H3	-3.09	-1.6 ± 0.3	0.007	0	0	a	LinJ.31.3250	Phosphatidylethanolamine N-methyltransferase, putative	-	1.0 ± 0.1
Lin243A10	-3.18	-1.7 ± 0.9	0.037	4e-125	1e-125	a	LinJ.31.3260	Methylcrotonyl-CoA carboxylase biotinylated subunit (MCCbt)	N.D.	-2.1 ± 0.3
Lin241A4	-2.84	-1.5 ± 0.3	0.014	3e-67	1e-23	a	LinJ.31.1640	Diphthine synthase-like protein (DpS)	+	
Lin282B9	-8.43	-3.1 ± 0.9	0.047	5e-177	0	b	LinJ.23.0290	Multi-drug resistance protein, putative (MRP)	N.D.	
Lin261G3	-2.12	-1.1 ± 0.3	0.028	0	0	a	LinJ.23.0620	Oxidoreductase-like protein (OXR)	N.D.	
Lin264E4	-2.15	-1.1 ± 0.1	0.003	0	0	a	LinJ.18.0370	Tubulin tyrosine ligase, putative (TubTyrL)	+	-10.1 ± 0.5
Lin289A6	-2.01	-1.0 ± 0.5	0.011	0	0	b	LinJ.28.1250	Long chain fatty acid:coenzyme A ligase, putative (LC-FACL)	N.D.	
Lin300A3	-2.28	-1.2 ± 0.2	0.032	0	0	b	LinJ.11.1240	ABC transporter, putative	N.D.	
Lin312B11	-2.15	-1.1 ± 0.2	0.019	3e-169	5e-171	b	LinJ.31.1870 LinJ.34.3460	Protein kinase-like protein (PK) Vacuolar ATP synthase α catalytic subunit, putative (vATPα)	N.D.	

Features described: clone number, fold change (down-regulation if $F \leq -2.0$), $\log_2 F$ and standard deviation (SD), Student's t-test p -value (p), clone definition (Def.; see Methods), TriTrypDB identifier, annotated gene function (including abbreviations defined in the text) and qRT-PCR outcome. Genes in grey (clones that overlap with more than one annotated gene): they are not differentially regulated (confirmed by qRT-PCR) or there is no evidence to support that they are differentially regulated in other cases (not determined by qRT-PCR)

protein-protein interactions in other organisms such RNase inhibitors, tropomyosin, tropomodulin and toll-like receptors. Each LRR motif has a sheet-turn-helix structure [44].

Metabolism, transport and signal transduction

The dihydroliipoamide dehydrogenase gene (DHLDH) is up-regulated in Pro-Pper, as well as some genes that participate in the respiratory chain. Namely, the cytochrome oxidase VIII subunit (coxVIII), the ATPase subunit 9 (ATP_{su}.9) and the F1 γ subunit of the ATP synthetase (F1 γ).

The up-regulation of the α -ketoisovalerate dehydrogenase gene (KIVDH) and the down-regulation of the methylcrotonyl-CoA carboxylase biotinylated subunit gene (MCCbt) suggest that isoleucine and valine catabolism may be favored in Pro-Pper, in agreement with the EC 1.2.4.4 and 6.4.1.4 activities of the KIVDH and MCCbt (Tables 2 and 3; TriTrypDB) within the KEGG pathway lif00280 [45].

A thiolase I gene (ACAT) is up-regulated in Pro-Pper, thus suggesting that β -oxidation of fatty acids is more active in this population than in Pro-PNA⁻. On the opposite, the long chain fatty acid:CoA ligase gene (LC-FACL) is down-regulated, which suggests that long chain fatty acids are a more common source for Pro-PNA⁻ to feed the β -oxidation degradation pathway or to contribute to fatty acid, glycerolipid and phospholipid biosynthesis (EC 6.2.1.3. activity in KEGG pathways ec00071 and ec00061, respectively). The lipin gene is also down-regulated and it is involved in glycerolipid biosynthesis. Consequently, these

data suggest that β -oxidation is more active in Pro-Pper, whereas the lipid biosynthetic processes would be favored in Pro-PNA⁻. Both pathways provide molecules that are active in signaling processes [46]. The sphingolipid biosynthetic pathway may be more active in Pro-Pper as suggested by up-regulation of the sphingolipid Δ^4 -desaturase gene (DECS). Sphingolipids are also able to develop signaling functions in the parasite [47].

Protein kinases of these parasites have been identified [48] but most signaling pathways are still not known in these organisms yet [49]. The genes encoding a serine/threonine protein phosphatase 1 LinJ.34.0840 (PP1), a serine/threonine protein phosphatase 2 catalytic subunit A2 (PP2B-A2), a dual specificity protein phosphatase (DualPP) and three PKs are up-regulated, whereas the phosphatidylinositol 3-kinase gene (PI3K) and a protein kinase gene (PK) are down-regulated.

The genes encoding the α subunit of the vacuolar ATP synthetase (vATP α) and the ABC transporters ABCE and ABC LinJ.11.0040 are up-regulated in Pro-Pper, whereas the multidrug resistance protein (MRP), the ABC LinJ.11.1240 and the ABC1 are down-regulated. Finally, a nucleotide binding protein (NBP-MRP), probably an MRP (see LinJ.21.0720 entry in TriTrypDB), is also down-regulated.

Cytoskeleton

Several genes encoding actin- and tubulin-interacting proteins (AIP and TIP) are up-regulated in Pro-Pper. The AIPs are the profilin, two ADP-ribosylation factors (ARF LinJ.31.2350 and ARF3) and the tubulin-tyrosine ligase





Fig. 4 Differentially regulated genes of known function in Pro-Pper/Pro-PNA⁻. Protein products in red correspond to genes up-regulated in Pro-Pper and those in green to Pro-PNA⁻. See abbreviations in the text and in Tables 2 and 3

(TubTyrL). The TubTyrL is also a TIP, as well as a coronin and the OSM3-like kinesin. A different ARF gene (LinJ.04.0470) is down-regulated. The ARF1 has been characterized in *T. cruzi* and in *L. donovani*, where it is involved in coatomer assembly in budding vesicles in the

secretory pathway and endocytosis [50, 51]. The profilin may be involved in the actin microfilament polymerization machinery [52]. Coronins of *Leishmania* spp., *Trypanosoma* spp. and other protozoan parasites are involved in proliferation, locomotion and phagocytosis [53].



Surface molecules

Biosynthesis of glycosylphosphatidylinositol (GPI) may be increased in Pro-Pper, as the genes encoding the GPI transamidase GAA1 component (GPIT-GAA1) and the GPI transamidase subunit 8 (GPIT.8) are up-regulated. The GPI is an essential anchor of important surface molecules, such as the gp63 metalloprotease. One of the genes encoding a gp63 is up-regulated in Pro-Pper. The gp63 has been traditionally associated to metacyclic promastigotes and increased infectivity [12, 54–56]. The GPI is also the essential anchor for glycosylinositolphospholipids (GIPLs) and other surface proteins of the amastigote glycocalix. GIPLs act as receptors for the host cell and as a shield for resistance against lysosomal hydrolases [57]. The GPI anchor is essential for the biosynthesis of GIPLs, which may partially explain the importance of up-regulating GPI-biosynthetic enzymes in metacyclic promastigotes, according to the pre-adaptation hypothesis [24, 58, 59]. The phosphoglycan β -1,3-galactosyltransferase (PG β 1,3GalT), also up-regulated in Pro-Pper, is involved in the biosynthesis of the lipophosphoglycan (LPG) and proteophosphoglycans (PPG), which are major surface molecules of promastigotes. The LPG is modified during promastigote differentiation, which makes possible negative selection with PNA.

The amastin superfamily genes LinJ.08.0680/0690/1320 are up-regulated in Pro-Pper vs. Pro-PNA⁻. They were described to be down-regulated in logarithmic phase promastigotes with respect to stationary phase promastigotes [24]. Some of these genes are up-regulated when temperature is raised and pH decreased both in axenic and intracellular amastigotes [24, 60]. Initially, these molecules were thought to be specific of the amastigote stage, but over-expression was also detected in stationary phase promastigotes and metacyclic promastigotes. Hence, they are up-regulated in advance prior to the

differentiation process of promastigotes to amastigotes, according to the pre-adaptation hypothesis [24, 58, 59].

Genes related with infectivity and preparation in advance to life in the phagolysosome

A Zn carboxypeptidase gene from the family M14 (ZnCP) is up-regulated in Pro-PNA⁻ with respect to Pro-PNA⁺ [26]. Despite it is not differentially regulated between Pro-Pper and Pro-PNA⁻, we found that it is up-regulated in Pro-Pper with respect to the whole stationary phase population [61]. This finding together with the differences in infectivity (Fig. 2) support that the degree of differentiation of the Pro-PNA⁻ subpopulation is higher than the whole population in stationary phase as previously reported [26] but lower than Pro-Pper (Fig. 2). The significantly higher infectivity of Pro-Pper promastigotes in terms of rate of infected cells and number of amastigotes per infected cell are in agreement with the higher expression levels of the gp63 gene and GPI, LPG and PPG biosynthetic genes GPIT.8, GPIT-GAA1, PG- β -1,3-GalT. Up-regulation of the SALp2 and amastin genes in Pro-Pper is also probably related. The Pearson correlation coefficient between Pro-Pper and Pro-PNA⁻ in terms of differential gene expression (normalized fluorescence intensity values) is $R^2 = 0.68$. The meaning of this finding is that both populations are strongly correlated. However, it reveals important differences at the same time because it is not close to the maximum value (1). This is clearly appreciated in the shape of the M/A scatter plot (Fig. 3), which is a non-dispersed (rank $-4 < M < 4$) dot-cloud symmetric about the $M = 0$ line (i.e., lack of differential expression).

The gp63 gene, the GPI, LPG and PPG biosynthetic genes and others may be involved in preparation in advance for differentiation and survival of the amastigote stage in the phagolysosome according to the pre-adaptative

hypothesis [24, 58, 59]. This is especially probable in the case of the amastin and the GPI biosynthetic protein genes.

Conclusions

The mean of amastigote counts per infected cell is significantly higher in Pro-Pper than in Pro-PNA⁻, as well as the rate of infected cells. Up-regulation of genes involved in GPI, LPG and PPG biosynthesis and a gp63 gene at the transcript level in Pro-Pper supports the differences found in infectivity. Consequently, the Pro-Pper population is more infective than the Pro-PNA⁻ one. Therefore, Pro-PNA⁻ are not as infective as Pro-Pper, but they are highly infective in any case. This means that enrichment in metacyclics by negative selection with PNA in culture is a good approach but not as good as isolation from the natural environment, i.e. the anterior thoracic midgut of the sand fly. Indeed, the Pearson correlation coefficient ($R^2 = 0.68$) between both transcriptomes in terms of transcript abundance supports that the similarity between both populations is moderate and the important differences found are presumably related to increased infectivity in Pro-Pper. In other words, the correlation is sufficiently high to consider that both samples are physiologically comparable (i.e. the experiment was correctly designed and performed) and sufficiently low to conclude that important differences in transcript abundance have been found (including genes involved in chromatin structure, nucleocytoplasmic transport, gene expression regulation, signaling and other processes). Therefore, the implications of axenic culture should be evaluated case-by-case in each experimental design even when the stationary phase population is enriched in metacyclic promastigotes by negative selection with PNA.

Additional files

Additional file 1: Primers and TaqMan-MGB probes used for qRT-PCR validation and determination of differential expression in clones that represent more than one gene. **Table S1.** Sequences of qRT-PCR primers and probes. (XLS 33 kb)

Additional file 2: Microarray controls. **Table S2.** The results of the Pro-Per/Pro-PNA⁻ cDNA:genomic-DNA-microarray hybridization analysis for positive and negative control spots. (DOC 48 kb)

Additional file 3: Hypothetical proteins. **Table S3.** Hypothetical protein genes up-regulated in Pro-Pper/Pro-PNA⁻. **Table S4.** Hypothetical protein genes down-regulated in Pro-Pper/Pro-PNA⁻. **Table S5.** Type c and qPCR non-determined clones. (DOC 255 kb)

Abbreviations

aaRNA: doubly amplified mRNA; ABC: ATP-binding cassette; ACAT: thiolase I; AIP: actin-interacting protein; ARF: ADP-ribosylation factor; aRNA: amplified mRNA; ATPsu.9: ATPase subunit 9; C2cp: calpain-like cysteine peptidase, Clan CA, family C2; CETN: centrin; coxVIII: cytochrome oxidase subunit VIII; CYP: cyclophilin; DECS: sphingolipid Δ^4 -desaturase; DHLDH: dihydrolipoamide dehydrogenase; DpS: diphthine synthase; DualPP: dual specificity protein phosphatase; DynLC: dynein light chain; EF1 β : elongation factor 1 β ; GPL: glycosylinositolphospholipid; gp63: 63 kDa glycoprotein,

metalloprotease (leishmanolysin); GPI: glycosylphosphatidylinositol; GPIT.8: GPI transamidase subunit 8; GPIT-GAA1: GPI transamidase GAA1 component; HIFBS: heat-inactivated fetal bovine serum; HMGCR: 3-hydroxymethylglutaryl-CoA reductase; IF2: initiation factor 2; KVDH: 2-ketoisovalerate dehydrogenase; LC-FACL: long chain fatty acid:CoA ligase; LPG: lipophosphoglycan; LRRP: leucine-rich repeat protein; MCCbt: methylcrotonyl-CoA carboxylase biotinylated subunit; mPPG: membrane-bound proteophosphoglycan; MRP: multidrug resistance protein; MVP: major vault protein; NBP: nucleotide-binding protein; NUDC: nuclear movement protein; OPB: oligopeptidase B; OXR: oxidoreductase; PDH: pyruvate dehydrogenase complex; PG β 1,3GalT: phosphoglycan β -1,3-galactosyltransferase; PI3K: phosphatidylinositol 3-kinase; PK: protein kinase; PNA: peanut agglutinin; PP1: Ser/Thr protein phosphatase 1; PP2B-A2: Ser/Thr protein phosphatase 2, catalytic subunit A2; Pro-PNA⁻: PNA non-agglutinating promastigotes; Pro-Pper: promastigotes isolated from the stomodeal valve of *P. perniciosus*; SALp2: surface antigen-like protein 2; SL-RNA: spliced leader RNA; sPPG: secreted proteophosphoglycan; TF: transcription factor; TIP: tubulin-interacting protein; TOR: target of rapamycin; TubTyrL: tubulin tyrosine ligase; UbH: ubiquitin hydrolase; UbqA-E1: ubiquitin-activating enzyme E1; vATPsa: vacuolar ATP synthetase, subunit α ; VL: visceral leishmaniasis; ZnCP: zinc carboxypeptidase, family M14.

Acknowledgments

We thank Alfredo Toraño, Mercedes Domínguez, Víctor Parro and Manuel J. Gómez for their support. This project was funded through the Ramón Areces Foundation contract 050204100014 (OTT code 20100338). PJA thanks CSIC for the I3P-BPD2003-1 grant and two contracts of employment for a position included in the A1 group (respectively from January 16th to July 23rd 2008 and from October 16th 2008 to April 15th 2009). AA thanks CSIC for the JaeDoc contract 5072160068 W0SC000077 within the A1 group. MAD thanks the Spanish Ministry of Economy and Competitiveness for the FPI predoctoral fellowship BES-2011-047361.

Availability of the supporting data

Microarray hybridization data are available in the MIAME-compliant GEO repository (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70992>). Particular information about the sequences of primers and TaqMan probes used, hybridization controls in the microarray experiment, hypothetical proteins and analysis by gene clustering is available in the Additional files associated to this manuscript. Gene identifiers listed in Tables 2 and 3 correspond to TriTrypDB.

Authors' contributions

All authors contributed to the intellectual content of the study and revised and approved the final manuscript. PJA, AA and VL conceived and designed the experiment. MIJ and RM performed the sand fly infection and dissection procedures and prepared Pro-Pper. MAD performed the in vitro infection assays. PJA, MIJ, MAD and RM prepared samples for microarray hybridization. PJA, MM and AA performed the microarray hybridization experiment. PJA and AA performed qRT-PCR analysis. PJA, AA and VL contributed to the thorough analysis and interpretation of the results and prepared the manuscript.

Competing interests

All authors declare that they have no competing interests.

Author details

¹Laboratorio de Parasitología Molecular, Departamento de Microbiología Molecular y Biología de las Infecciones, Centro de Investigaciones Biológicas (Consejo Superior de Investigaciones Científicas), calle Ramiro de Maeztu, 9, 28040 Madrid, Spain. ²Laboratorio de Ecología Molecular, Centro de Astrobiología, (Instituto Nacional de Técnica Aeroespacial "Esteban Terradas"-Consejo Superior de Investigaciones Científicas), ctra. de Ajalvir Km 4, 28850 Torrejón de Ardoz, Madrid, Spain. ³Unidad de Entomología Médica, Servicio de Parasitología, Centro Nacional de Microbiología, Virología e Inmunología Sanitarias (Instituto de Salud Carlos III), ctra. Majadahonda-Pozuelo s/n, 28220 Majadahonda, Madrid, Spain.

Received: 18 July 2015 Accepted: 26 April 2016

Published online: 20 May 2016

References

- Desjeux P. Leishmaniasis. Public health aspects and control. *Clin Dermatol*. 1996;14(5):417–23.
- WHO. Report of a meeting of the WHO Expert Committee on the control of Leishmaniases. Geneva: WHO; 2010.
- Pasquau F, Ena J, Sanchez R, Cuadrado JM, Amador C, Flores J, Benito C, Redondo C, Lacruz J, Abril V. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. *Eur J Clin Microbiol Infect Dis*. 2005;24(6):411–8.
- Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/HIV co-infections in the second decade. *Indian J Med Res*. 2006;123(3):357–88.
- Arce A, Estirado A, Ordoñas M, Sevilla S, García N, Moratilla L, de la Fuente S, Martínez AM, Pérez AM, Aranguéz E. Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. *Euro Surveill*. 2013;18(30):20546.
- Molina R, Jimenez M, Cruz I, Iriso A, Martín-Martin I, Sevillano O, Melero S, Bernal J. The hare (*Lepus granatensis*) as potential sylvatic reservoir of *Leishmania infantum* in Spain. *Vet Parasitol*. 2012;190(1–2):268–71.
- Jimenez M, Gonzalez E, Martín-Martin I, Hernandez S, Molina R. Could wild rabbits (*Oryctolagus cuniculus*) be reservoirs for *Leishmania infantum* in the focus of Madrid, Spain? *Vet Parasitol*. 2014;202(3–4):296–300.
- da Silva R, Sacks DL. Metacyclogenesis is a major determinant of *Leishmania* promastigote virulence and attenuation. *Infect Immun*. 1987;55(11):2802–6.
- Gossage SM, Rogers ME, Bates PA. Two separate growth phases during the development of *Leishmania* in sand flies: implications for understanding the life cycle. *Int J Parasitol*. 2003;33(10):1027–34.
- Rioux JA, Guilvard E, Gállego J, Moreno G, Pratlong F, Portús M, Rispaill P, Gállego M, Bastien P. *Phlebotomus ariasi* Tonnoir, 1921 et *Phlebotomus perniciosus* Newstead, 1911 vecteurs du complexe *Leishmania infantum* dans un même foyer. Infestations par deux zymodèmes syntopiques. A propos d'une enquête en Catalogne (Espagne). In: Rioux JA, editor. "Leishmania" Taxonomie et phylogénèse Applications éco-épidémiologiques Int Coll CNRS/INSERM/OMS 1984. Montpellier: Institut Méditerranéen d'Etudes Epidémiologiques et Ecologiques; 1986. p. 439–44.
- Killick-Kendrick R. The biology and control of phlebotomine sand flies. *Clin Dermatol*. 1999;17(3):279–89.
- Joshi PB, Sacks DL, Modi G, McMaster WR. Targeted gene deletion of *Leishmania* major genes encoding developmental stage-specific leishmanolysin (GP63). *Mol Microbiol*. 1998;27(3):519–30.
- McConville MJ, Mullin KA, Ilgoutz SC, Teasdale RD. Secretory pathway of trypanosomatid parasites. *Microbiol Mol Biol Rev*. 2002;66(1):122–54. table of contents.
- Pimenta PF, Turco SJ, McConville MJ, Lawyer PG, Perkins PV, Sacks DL. Stage-specific adhesion of *Leishmania* promastigotes to the sandfly midgut. *Science*. 1992;256(5065):1812–5.
- Sacks DL, Perkins PV. Identification of an infective stage of *Leishmania* promastigotes. *Science*. 1984;223(4643):1417–9.
- Sacks DL, Perkins PV. Development of infective stage *Leishmania* promastigotes within phlebotomine sand flies. *Am J Trop Med Hyg*. 1985;34(3):456–9.
- Neal RA, Miles RA. Heated blood agar medium for the growth of *Trypanosoma cruzi* and some species of *Leishmania*. *Nature*. 1963;198:210–1.
- Lemma A, Schiller EL. Extracellular cultivation of the leishmanial bodies of species belonging to the Protozoan Genus *Leishmania*. *Exp Parasitol*. 1964;15:503–13.
- Steiger RF, Steiger E. A defined medium for cultivating *Leishmania donovani* and *L. braziliensis*. *J Parasitol*. 1976;62(6):1010–1.
- Berens RL, Marr JJ. An easily prepared defined medium for cultivation of *Leishmania donovani* promastigotes. *J Parasitol*. 1978;64(1):160.
- Zilberstein D. Physiological and biochemical aspects of *Leishmania* development. In: Myler P, Fassel N, editors. *Leishmania after the genome*. Norfolk: Caister Academic Press; 2008. p. 107–22.
- Zuckerman A, Lainson R. *Leishmania*. In: Kreier JP, editor. *Parasitic protozoa*. New York: Academic; 1977. p. 66–86.
- Alcolea PJ, Alonso A, Gomez MJ, Postigo M, Molina R, Jimenez M, Larraga V. Stage-specific differential gene expression in *Leishmania infantum*: from the foregut of *Phlebotomus perniciosus* to the human phagocyte. *BMC Genomics*. 2014;15:849.
- Alcolea PJ, Alonso A, Gomez MJ, Moreno I, Dominguez M, Parro V, Larraga V. Transcriptomics throughout the life cycle of *Leishmania infantum*: high down-regulation rate in the amastigote stage. *Int J Parasitol*. 2010;40(13):1497–516.
- McConville MJ, Turco SJ, Ferguson MA, Sacks DL. Developmental modification of lipophosphoglycan during the differentiation of *Leishmania* major promastigotes to an infectious stage. *EMBO J*. 1992;11(10):3593–600.
- Alcolea PJ, Alonso A, Sanchez-Gorostiaga A, Moreno-Paz M, Gomez MJ, Ramos I, Parro V, Larraga V. Genome-wide analysis reveals increased levels of transcripts related with infectivity in peanut lectin non-agglutinated promastigotes of *Leishmania infantum*. *Genomics*. 2009;93(6):551–64.
- Sacks DL, Hieny S, Sher A. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of *Leishmania* major promastigotes. *J Immunol*. 1985;135(1):564–9.
- Sacks DL. Metacyclogenesis in *Leishmania* promastigotes. *Exp Parasitol*. 1989;69(1):100–3.
- Spath GF, Beverley SM. A lipophosphoglycan-independent method for isolation of infective *Leishmania* metacyclic promastigotes by density gradient centrifugation. *Exp Parasitol*. 2001;99(2):97–103.
- Alcolea PJ, Alonso A, Garcia-Tabares F, Torano A, Larraga V. An insight into the proteome of *Crithidia fasciculata* choanostigotes as a comparative approach to axenic growth, peanut lectin agglutination and differentiation of *Leishmania* spp. promastigotes. *PLoS One*. 2014;9(12), e113837.
- Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). *Int J Cancer*. 1976;17(5):565–77.
- Minta JO, Pambrun L. In vitro induction of cytologic and functional differentiation of the immature human monocyte-like cell line U-937 with phorbol myristate acetate. *Am J Pathol*. 1985;119(1):111–26.
- Molina R. Experimental infections of a *Phlebotomus perniciosus* colony using different procedures. *Parassitologia*. 1991;33(Suppl):425–9.
- Molina R. Laboratory adaptation of an autochthonous colony of *Phlebotomus perniciosus* Newstead, 1911 (Diptera: Phlebotomidae). *Res Rev Parasitol*. 1991; 1991(51):87–9.
- Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. In: Ausubel FM et al, editors. *Current protocols in molecular biology*. 2006. Chapter 15:Unit 15 18.
- Charest H, Zhang WW, Matlashewski G. The developmental expression of *Leishmania donovani* A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region. *J Biol Chem*. 1996;271(29):17081–90.
- Lahav T, Sivam D, Volpin H, Ronen M, Tsigankov P, Green A, Holland N, Kuzyk M, Borchers C, Zilberstein D, et al. Multiple levels of gene regulation mediate differentiation of the intracellular pathogen *Leishmania*. *FASEB J*. 2011; 25(2):515–25.
- Parsons M, Myler PJ, Berriman M, Roos DS, Stuart KD. Identity crisis? The need for systematic gene IDs. *Trends Parasitol*. 2011;27(5):183–4.
- Soto M, Requena JM, Quijada L, Alonso C. Organization, transcription and regulation of the *Leishmania infantum* histone H3 genes. *Biochem J*. 1996; 318(Pt 3):813–9.
- Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. *Cancer Res*. 1995;55(19):4214–9.
- Saldivia M, Barquilla A, Bart JM, Diaz-Gonzalez R, Hall MN, Navarro M. Target of rapamycin (TOR) kinase in *Trypanosoma brucei*: an extended family. *Biochem Soc Trans*. 2013;41(4):934–8.
- Alcolea PJ, Alonso A, Larraga V. Genome-wide gene expression profile induced by exposure to cadmium acetate in *Leishmania infantum* promastigotes. *Int Microbiol*. 2011;14(1):1–11.
- Moehring JM, Moehring TJ. The post-translational trimethylation of diphthamide studied in vitro. *J Biol Chem*. 1988;263(8):3840–4.
- Kobe B, Deisenhofer J. The leucine-rich repeat: a versatile binding motif. *Trends Biochem Sci*. 1994;19(10):415–21.
- Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. *Nucleic Acids Res*. 2004;32(Database issue):D277–80.
- Zhang K, Beverley SM. Phospholipid and sphingolipid metabolism in *Leishmania*. *Mol Biochem Parasitol*. 2010;170(2):55–64.
- Zhang K, Bangs JD, Beverley SM. Sphingolipids in parasitic protozoa. *Adv Exp Med Biol*. 2010;688:238–48.
- Parsons M, Worthey EA, Ward PN, Mottram JC. Comparative analysis of the kinomes of three pathogenic trypanosomatids: *Leishmania major*, *Trypanosoma brucei* and *Trypanosoma cruzi*. *BMC Genomics*. 2005;6:127.

49. Parsons M, Ruben L. Pathways involved in environmental sensing in trypanosomatids. *Parasitol Today*. 2000;16(2):56–62.
50. de Sa-Freire A, Nepomuceno-Silva JL, da Paixao JC, de Mendonca SM, de Melo LD, Lopes UG. TcArf1: a *Trypanosoma cruzi* ADP-ribosylation factor. *Parasitol Res*. 2003;91(2):166–70.
51. Porter-Kelley JM, Gerald NJ, Engel JC, Ghedin E, Dwyer DM. LdARF1 in trafficking and structural maintenance of the trans-Golgi cisternal network in the protozoan pathogen *Leishmania donovani*. *Traffic*. 2004;5(11):868–83.
52. Marion S, Laurent C, Guillen N. Signalization and cytoskeleton activity through myosin IB during the early steps of phagocytosis in *Entamoeba histolytica*: a proteomic approach. *Cell Microbiol*. 2005;7(10):1504–18.
53. Xavier CP, Eichinger L, Fernandez MP, Morgan RO, Clemen CS. Evolutionary and functional diversity of coronin proteins. *Subcell Biochem*. 2008;48:98–109.
54. Halle M, Gomez MA, Stuibler M, Shimizu H, McMaster WR, Olivier M, Tremblay ML. The *Leishmania* surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. *J Biol Chem*. 2009;284(11):6893–908.
55. Brittingham A, Morrison CJ, McMaster WR, McGwire BS, Chang KP, Mosser DM. Role of the *Leishmania* surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. *J Immunol*. 1995;155(6):3102–11.
56. Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. *PLoS Pathog*. 2009;5(8), e1000559.
57. Blackwell JM, Ezekowitz RA, Roberts MB, Channon JY, Sim RB, Gordon S. Macrophage complement and lectin-like receptors bind *Leishmania* in the absence of serum. *J Exp Med*. 1985;162(1):324–31.
58. Bates PA. *Leishmania* sand fly interaction: progress and challenges. *Curr Opin Microbiol*. 2008;11(4):340–4.
59. Depledge DP, Evans KJ, Ivens AC, Aziz N, Maroof A, Kaye PM, Smith DF. Comparative expression profiling of *Leishmania*: modulation in gene expression between species and in different host genetic backgrounds. *PLoS Negl Trop Dis*. 2009;3(7), e476.
60. Alcolea PJ, Alonso A, Gomez MJ, Sanchez-Gorostiaga A, Moreno-Paz M, Gonzalez-Pastor E, Torano A, Parro V, Larraga V. Temperature increase prevails over acidification in gene expression modulation of amastigote differentiation in *Leishmania infantum*. *BMC Genomics*. 2010;11:31.
61. Alcolea PJ, Alonso A, Domínguez M, Parro V, Jiménez M, Molina R, Larraga V. Influence of the microenvironment in the transcriptome of *Leishmania infantum* promastigotes: sand fly versus culture. *PLoS Negl Trop Dis*. 2016; 10(5):e0004693.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

